Trust Co. of Vermont Reduces Investment in AbbVie Inc
June 23, 2023
☀️Trending News
ABBVIE ($NYSE:ABBV): Trust Co. of Vermont recently announced that it had reduced its investment in AbbVie Inc, a biopharmaceutical company that is primarily focused on developing treatments for various conditions, such as chronic autoimmune, neurological, and rare diseases. It is not known why Trust Co. of Vermont has reduced its investment in AbbVie Inc, however, it is likely due to the current volatility of the stock market and the uncertainty surrounding the healthcare industry. It is also possible that the trust company may be looking to diversify its portfolio. In any case, investors should monitor the situation closely and make sure to do their own research before investing in AbbVie Inc or any other company.
Share Price
On Tuesday, the trust company of Vermont made a noteworthy move by reducing their investment in AbbVie Inc. The company’s stock opened at $137.1 and closed at $137.8, representing a decrease of 0.6% from the previous closing price of 138.6. This is significant news for AbbVie Inc, though it is unclear what effect this decision will have on the company in the long-term. Live Quote…
About the Company
Income Snapshot
Below shows the total revenue, net income and net margin for Abbvie Inc. More…
| Total Revenues | Net Income | Net Margin |
| 56.74k | 7.55k | 14.6% |
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for Abbvie Inc. More…
| Operations | Investing | Financing |
| 24.94k | -623 | -24.8k |
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for Abbvie Inc. More…
| Total Assets | Total Liabilities | Book Value Per Share |
| 138.81k | 121.52k | 9.78 |
Key Ratios Snapshot
Some of the financial key ratios for Abbvie Inc are shown below. More…
| 3Y Rev Growth | 3Y Operating Profit Growth | Operating Margin |
| 18.5% | 6.9% | 23.2% |
| FCF Margin | ROE | ROA |
| 42.7% | 47.6% | 5.9% |
Analysis
GoodWhale recently conducted an analysis of ABBVIE INC‘s fundamentals. Our Risk Rating has classified ABBVIE INC as a medium risk investment in both financial and business aspects. We have detected two risk warnings in the company’s balance sheet, which are non-financial. If you would like to know more, please register with us to get full and detailed insights into the ABBVIE INC’s financial and business risk profile. More…
Peers
AbbVie Inc is a global, research-based biopharmaceutical company formed in 2013. AbbVie combines the focus and passion of a leading-edge biotech with the experience and breadth of a long-established pharmaceutical leader to develop and market advanced therapies that address some of the world’s most complex and serious diseases.
Kwang Dong Pharmaceutical Co Ltd, Jiangsu Hengrui Pharmaceuticals Co Ltd, Vivesto AB are all competitors of AbbVie Inc.
– Kwang Dong Pharmaceutical Co Ltd ($KOSE:009290)
Kwang Dong Pharmaceutical Co Ltd is a South Korean company that manufactures and sells pharmaceutical products. The company has a market cap of 233.75 billion as of 2022 and a return on equity of 19.33%. Kwang Dong Pharmaceutical Co Ltd manufactures a wide range of pharmaceutical products, including antibiotics, anti-inflammatory drugs, and cardiovascular drugs. The company also has a research and development department that is responsible for developing new drugs and formulations.
– Jiangsu Hengrui Pharmaceuticals Co Ltd ($SHSE:600276)
Jiangsu Hengrui Pharmaceutical Co., Ltd. is a Chinese pharmaceutical company that engages in the research, development, manufacture, and sale of chemical and biological drugs in China and internationally. The company has a market cap of 248.78 billion as of 2022 and a return on equity of 6.72%. Jiangsu Hengrui Pharmaceutical Co., Ltd. is headquartered in Lianyungang, China.
– Vivesto AB ($OTCPK:OASMY)
Vivesto AB is a Swedish company that provides financial technology solutions. The company has a market capitalization of 32.61 million as of 2022 and a return on equity of -9.39%. Vivesto’s products and services include online banking, mobile banking, and payments solutions. The company serves retail, corporate, and institutional clients.
Summary
Investing in AbbVie Inc has been a lucrative opportunity for investors. Recently, Trust Co. of Vermont decreased its stake in the company as part of a portfolio rebalancing strategy. The company’s strong financials, high dividend payout and diversified portfolio of products have made it an attractive investment opportunity for investors. Overall, AbbVie Inc is a strong investment opportunity for investors looking for a reliable and profitable long-term hold.
Related Posts
Recent Posts
Investing Everyone Can Do.
Investing shouldn’t be exclusive to a select few. We believe everyone should have the opportunity to grow their wealth. That’s why our app is designed to be accessible and user-friendly, even for beginners.
